Huma completes Series D as it launches Huma Cloud Platform with GenAI integrations to bring digital-first care and research

Huma completes Series D as it launches Huma Cloud Platform with GenAI integrations to bring digital-first care and research

Building and launching a scalable digital health product that meets regulatory demands typically takes a few years to deliver. Global healthcare AI company Huma Therapeutics has announced the completion of its Series D funding round to help cut that time down to days as it launches the Huma Cloud Platform. The platform offers no-code configuration of regulated disease management tools for any therapeutic area, a library of pre-built modules and device connectivity capabilities, a cloud-agnostic framework for flexible hosting, readily available APIs and integration capabilities, the ability to host and deploy diagnostic and predictive AI algorithms, a marketplace, and more to advance digital-first care and research.

Alongside its Series D, Huma is also announcing the launch of its Huma Cloud Platform – a technology ecosystem designed not only to support the company’s own digital health initiatives, but also to empower others to launch and scale their projects efficiently. With its Huma Cloud Platform and the regulatory foundation that it is built on, Huma aims to reduce the time it takes to develop and launch digital health projects at scale from years to as little as a few days.

The Huma Cloud Platform is built to serve the company’s existing regulated products. In 2023, Huma achieved the landmark milestone of becoming the first and only configurable, disease-agnostic FDA Class II, EuMDR Class IIb, and Saudi FDA Class C platform, enabling rapid, code-free configuration with the ability to host AI/ML models. This regulatory status significantly reduces the cost, time, and risks associated with bringing digital health projects to life through the Huma Cloud Platform.

Huma is now making this platform available to customers which comes with a Software Development Kit (SDK) to enable the accelerated development of similar applications or to embed functionalities into their existing solutions.

Dr Juergen Eckhardt, EVP, Head of Leaps by Bayer and Pharmaceuticals Business, Development and Licensing, said: “Pharmaceutical companies need financially and technically efficient digital solutions to minimise spending on efforts that are duplicative or can’t scale. The Huma Cloud Platform enables companies to streamline how they bring digital medicine, companion apps, and data collection capabilities to patients from the R&D phase to post-launch.”

Huma has partnered with Google and others to develop new AI models that could enable its Cloud Platform users to care for many times more patients with less work; for example, a feature called ‘10x Nurse’ that significantly reduces administrative tasks and brings automation to the patient review process with a human in the loop.

Dan Vahdat, Founder and CEO of Huma, added: “We are here to accelerate the adoption of digital and AI across care and research, and we do that by making the building of digital health solutions for care and research easy. We like to think of Huma Cloud Platform much like Shopify but for digital health instead of e-commerce. We believe when digital and AI are scaled, they become affordable for both the poor and the rich. They remain consistent and will help us transition medicine from being reactive to proactive.”

Click below to share this article